
Nextech Invest Ltd.
About Nextech Invest Ltd.’s 13F portfolio
Nextech Invest Ltd. is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Nextech Invest Ltd. reported $2.1B across 15 US-listed positions (). Its largest position is REVOLUTION MEDICINES INC (RVMD) at 68% of the reported book, and its ten biggest holdings make up 98% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: RVMD REVOLUTION MEDICINES INC | $159.43 −0.24% | 68% | 7.6M | $1.4B |
| 2 | NASDAQ: PBLS PARABILIS MEDICINES INC | — — | 6.1% | 4.7M | $127.6M |
| 3 | NASDAQ: RLAY RELAY THERAPEUTICS INC | $15.91 −3.63% | 6.0% | 6.8M | $126.8M |
| 4 | NASDAQ: TYRA TYRA BIOSCIENCES INC | $19.73 +0.61% | 5.4% | 3.6M | $113.5M |
| 5 | NASDAQ: ALMS ALUMIS INC | $4.33 −1.48% | 4.7% | 3.5M | $99.6M |
| 6 | NASDAQ: ORIC ORIC PHARMACEUTICALS INC | $7.70 +0.65% | 3.7% | 7.2M | $77.6M |
| 7 | NASDAQ: KYMR KYMERA THERAPEUTICS INC | $119.39 −1.44% | 1.5% | 279K | $32.0M |
| 8 | NASDAQ: ZYME ZYMEWORKS INC | $26.86 +3.15% | 1.4% | 1.1M | $29.1M |
| 9 | NASDAQ: GLUE MONTE ROSA THERAPEUTICS INC | $8.91 −1.76% | 0.9% | 761K | $18.4M |
| 10 | NASDAQ: ARVN AVALO THERAPEUTICS INC | $6.74 −0.37% | 0.8% | 1.1M | $17.1M |
| 11 | NASDAQ: CTMX CYTOMX THERAPEUTICS INC. | $2.05 +9.04% | 0.8% | 4.4M | $16.7M |
| 12 | NASDAQ: SLN SILENCE THERAPEUTICS PLC | $19.81 −0.05% | 0.5% | 952K | $10.5M |
| 13 | NASDAQ: CRVS CORVUS PHARMACEUTICALS INC | $10.01 −1.77% | 0.3% | 450K | $6.7M |
| 14 | NASDAQ: CNTX CONTEXT THERAPEUTICS INC | $0.17 +1.32% | 0.2% | 7.4M | $4.1M |
| 15 | NASDAQ: ENGN ENGENE THERAPEUTICS INC | $1.76 −4.86% | 0.2% | 2.3M | $4.0M |
Showing the 15 largest positions reported in this 13F.
- Healthcare94%
- NewPBLSPARABILIS MEDICINES INC—$127.6M
- AddedRLAYRELAY THERAPEUTICS INC+22.6%$126.8M
- AddedGLUEMONTE ROSA THERAPEUTICS INC+150%$18.4M
- AddedARVNAVALO THERAPEUTICS INC+108%$17.1M
- NewENGNENGENE THERAPEUTICS INC—$4.0M
- ReducedTYRATYRA BIOSCIENCES INC−12.4%$113.5M
- SoldSPRYARS PHARMACEUTICALS INC−100%—
- SoldTNGXTANGO THERAPEUTICS INC−100%—
- SoldCGEMCULLINAN THERAPEUTICS INC−100%—
- SoldENGNENGENE HOLDINGS INC−100%—
Reading Nextech Invest Ltd.’s 13F portfolio
Nextech Invest Ltd.’s $2.1B 13F book is spread across 15 reported positions and is highly concentrated — its ten largest positions alone are 98% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are RVMD, PBLS, RLAY, TYRA and ALMS, led by REVOLUTION MEDICINES INC (RVMD) at 68% of the portfolio. The heaviest sector exposure is Healthcare (94%).
What Nextech Invest Ltd. changed last quarter
Between 2026-03-31 and Q2 2026, Nextech Invest Ltd. was roughly balanced between buying and selling: it opened 2 new positions and added to 3 more, while trimming 1 and closing 4 outright. Against a 15-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was PARABILIS MEDICINES INC (PBLS), and its biggest reduction was TYRA BIOSCIENCES INC (TYRA).
What a 13F does and doesn’t reveal
A 13F captures only Nextech Invest Ltd.’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Nextech Invest Ltd. is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Nextech Invest Ltd.'s profile on this page is built directly from those filings.
How current is the 13F data on Nextech Invest Ltd.'s page?
It reflects Nextech Invest Ltd.'s most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Nextech Invest Ltd. files its next quarterly report, this page refreshes automatically.
Can I see Nextech Invest Ltd.'s complete list of holdings?
This page highlights Nextech Invest Ltd.'s largest positions rather than all 15 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Nextech Invest Ltd.'s filings.
Does a 13F show everything Nextech Invest Ltd. owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Nextech Invest Ltd.'s book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Nextech Invest Ltd. made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

